Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Cost of Revenue (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Cost of Revenue for 17 consecutive years, with $63.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 57.11% to $63.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $247.9 million, a 1.7% decrease, with the full-year FY2025 number at $247.9 million, down 1.7% from a year prior.
  • Cost of Revenue was $63.0 million for Q4 2025 at Myriad Genetics, up from $43.8 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $266.8 million in Q4 2022 to a low of $40.1 million in Q4 2024.
  • A 5-year average of $69.5 million and a median of $57.7 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 966.67% in 2021, then crashed 65.01% in 2024.
  • Myriad Genetics' Cost of Revenue stood at $45.8 million in 2021, then surged by 482.53% to $266.8 million in 2022, then crashed by 57.05% to $114.6 million in 2023, then plummeted by 65.01% to $40.1 million in 2024, then surged by 57.11% to $63.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Cost of Revenue are $63.0 million (Q4 2025), $43.8 million (Q3 2025), and $79.4 million (Q2 2025).